Head-To-Head Comparison: PACS Group (NYSE:PACS) & Aclarion (NASDAQ:ACON)

PACS Group (NYSE:PACS) and Aclarion (NASDAQ:ACON) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Institutional and Insider Ownership

7.5% of Aclarion shares are owned by institutional investors. 70.4% of PACS Group shares are owned by company insiders. Comparatively, 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

PACS Group has a beta of -0.64, indicating that its share price is 164% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.

Profitability

This table compares PACS Group and Aclarion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PACS Group	3.62%	22.55%	3.45%
Aclarion	-9,517.11%	-52.31%	-49.79%

Valuation and Earnings

This table compares PACS Group and Aclarion”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29 billion	0.90	$191.54 million	$1.23	24.74
Aclarion	$80,000.00	32.51	-$7.23 million	($17.01)	-0.18

PACS Group has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for PACS Group and Aclarion, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0	1	4	1	3.00
Aclarion	1	0	0	0	1.00

PACS Group currently has a consensus price target of $44.40, suggesting a potential upside of 45.89%. Given PACS Group’s stronger consensus rating and higher possible upside, analysts clearly believe PACS Group is more favorable than Aclarion.

Summary

PACS Group beats Aclarion on 12 of the 15 factors compared between the two stocks.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.